Research Chemical Designation & Liability

Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.

Full Disclaimer
Archive Identifier

Efruxifermin

Metabolic & Weight Loss

Molecular Dossier

  • Rank Index: 47
  • Status: Phase 3 Clinical
  • What does this mean?
  • Molecular Structure: MW: ~43 kDa (FGF-21 + fatty acid conjugate) | Recombinant protein, extended half-life

About Efruxifermin

Efruxifermin (EFX, Roche) is a long-acting analogue of fibroblast growth factor 21 (FGF-21), modified with a fatty acid conjugate for extended half-life (~35 days vs. native FGF-21 ~7 hrs). FGF-21 activates FGFR1c/KLB co-receptor signaling to improve insulin sensitivity, reduce liver fat, increase adiponectin, and promote fat oxidation — effects particularly pronounced in the liver. Phase 2b HARMONY trial (MASH, 2024) randomized 600+ patients and showed 47% of efruxifermin-treated subjects achieved MASH resolution (histological improvement in steatosis, inflammation, ballooning without worsening of fibrosis) vs. 15% placebo. Liver fat reduction reached −40% MRI-PDFF at high doses. Phase 3 trials (SUMMIT1, SUMMIT2) are ongoing as of May 2026, with FDA review expected 2026–2027. Administered as once-weekly or every-two-weeks subcutaneous injection. Gastrointestinal side effects are minimal compared to GLP-1 class. The mechanism is hepatocyte-centric rather than appetite-suppressive, making it an attractive combination therapy partner for GLP-1 agonists in subjects with concurrent obesity + MASH.

Clinical Focus

FGF-21 Analogue — Hepatic Fat Reduction & MASH Treatment

Archival Aliases

EFX, FGF-21 Analogue, Pegbelfermin (related compound)

Frequently Asked Questions

Clinical Data Matrix

Parameter Clinical Value
Molecular Weight MW: ~43 kDa (FGF-21 + fatty acid conjugate) | Recombinant protein, extended half-life
Primary Pathway Metabolic & Weight Loss
Research Phase Phase 3 Clinical

Clinical Pros

  • Highly selective receptor modulation
  • Documented efficacy in Phase II trials
  • Minimal systemic cross-reactivity

Research Limitations

  • Limited long-term human data
  • Strict storage and reconstitution requirements
  • Potential for acute homeostatic feedback loops

Community Discussion

Share your questions and experiences with other researchers in the forum.

Discuss in Forum

Clinical Reference Nodes

[REF 1] pubmed.ncbi.nlm.nih.gov
[REF 2] clinicaltrials.gov
[REF 3] roche.com

Data Verified: 2026-05-07

Synergistic Matrix